EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Ameliorating effect of probiotics in a rat model of chronic kidney disease

Takio Inatomi iD, Mihoko Honma

PLOS ONE · 30.03.2023 · 18 (3) · e0281745

DOI: 10.1371/journal.pone.0281745 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 30.03.2023. Verfasst von Takio Inatomi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Inatomi Animal Hospital, Ota-ku, Tokyo, Japan. Hauptthemen laut MEDLINE: Probiotics, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic kidney disease is a prevalent and significant disease worldwide. This study investigated the effects of a medicinal probiotic (BIO-THREE, TOA Biopharma Co., Ltd, Tokyo, Japan) with safety assurance that contained Bacillus subtilis TO-A, Enterococcus faecium T-110, and Clostridium butyricum TO-A in chronic kidney disease. BIO-THREE was approved as a medical drug by the Japanese Ministry of Health, Labour and Welfare and is widely used in the human medical field to improve various symptoms caused by abnormal intestinal microflora. Sixty male rats were randomly assigned to three groups: (1) normal group (n = 20, group 1), rats were given a normal diet for 3 weeks, followed by phosphate-buffered solution (once daily, orally) and a normal diet for 4 weeks; (2) control group (n = 20, Group 2), rats were given a normal diet including 0.75% adenine for 3 weeks, followed by phosphate-buffered saline (once daily, orally) and a normal diet for 4 weeks; and (3) probiotic group (n = 20, Group 3), rats were given a normal diet including 0.75% adenine for 3 weeks, followed by probiotics (once daily, orally) and a normal diet for 4 weeks. Probiotic administration resulted in a decrease in intestinal pH by increasing short-chain fatty acid (SCFA) production, and consequently suppressed the production of urea toxin production, thus, protecting renal function. The lower intestinal pH also promoted a reduction in the blood phosphorus levels by promoting ionisation of calcium and its binding to free phosphorus. This probiotic-induced increase in SCFA production reduced intestinal permeability, inhibited blood lipopolysaccharide and urea toxin production, and prevented the weakening of muscle function and strength. Moreover, it improved dysbiosis in the gut. This study shows the potential of this probiotics approved as medicinal drug to reduce chronic kidney disease progression, especially where safety is required. Further studies are warranted to validate these findings in humans.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProbioticsRenal Insufficiency, ChronicHumansRatsAnimalsMaleFatty Acids, VolatileUreaAdeninePhosphates

Substanzen

Fatty Acids, VolatileUreaAdeninePhosphates

Autor:innen und Institutionen

  • Inatomi Animal Hospital, Ota-ku, Tokyo, Japan.
  • Kusama Animal Health Laboratory, Kashima-shi, Saga, Japan.

ORCID-Profile: Takio Inatomi

Zitieren

APA

Inatomi, T., & Honma, M. (2023). Ameliorating effect of probiotics in a rat model of chronic kidney disease. PLOS ONE, 18(3), e0281745. https://doi.org/10.1371/journal.pone.0281745

Vancouver

Inatomi T, Honma M. Ameliorating effect of probiotics in a rat model of chronic kidney disease. PLOS ONE. 2023;18(3):e0281745. doi:10.1371/journal.pone.0281745

BibTeX
@article{Inatomi2023,
  author = {Inatomi, Takio and Honma, Mihoko},
  title = {Ameliorating effect of probiotics in a rat model of chronic kidney disease},
  journal = {PLOS ONE},
  year = {2023},
  volume = {18},
  number = {3},
  pages = {e0281745},
  doi = {10.1371/journal.pone.0281745}
}
Kostenlos starten →